A randomized, double-blind, placebo-controlled, six-sequence crossover, Human Abuse Liability (HAL) study evaluating the abuse potential of JZP-110 relative to the Schedule IV stimulant phentermine

Trial Profile

A randomized, double-blind, placebo-controlled, six-sequence crossover, Human Abuse Liability (HAL) study evaluating the abuse potential of JZP-110 relative to the Schedule IV stimulant phentermine

Completed
Phase of Trial: Phase II

Latest Information Update: 21 Jun 2016

At a glance

  • Drugs JZP 110 (Primary) ; Phentermine
  • Indications Depressive disorders; Narcolepsy; Sleep apnoea syndrome
  • Focus Therapeutic Use
  • Acronyms HAL
  • Most Recent Events

    • 21 Jun 2016 New trial record
    • 14 Jun 2016 Primary endpoint has been met. (Liking at the Moment across the first 12 hours of all doses of JZP-110 compared to 90mg of Phentermine), as reported in a Jazz Pharmaceuticals media release.
    • 14 Jun 2016 According to a Jazz Pharmaceuticals media release, results from this study were presented at the 30th Associated Professional Sleep Societies (APSS) Annual SLEEP Meeting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top